Novel targeting using nanoparticles: An approach to the development of an effective anti-leishmanial drug-delivery system

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 877-890

  Ribeiro, Tatiana G ^a   Chávez Fumagall, Miguel A ^a   Valadares, Diogo G ^a   França, Juçara R ^a   Rodrigues, Lívia B ^a   Duarte, Mariana C ^a   Lage, Paula S ^a   Andrade, Pedro H R ^a   Lage, Daniela P ^a   Arruda, Leonardo V ^b,c   Refidaff, Cref ^b,c   Costa, Lourena E ^a   Martins, Vivian T ^a   Tavares, Carlos A P ^a   Castilho, Rachel O ^a   Coelho, Eduardo A F ^a   Faraco, André A G ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Amphotericin B.; Chitosan; Chondroitin; Leishmania spp; Nanoparticles

Indexed keywords

AMPHOTERICIN B; CHITOSAN; CHONDROITIN SULFATE; NANOPARTICLE; ANTITRYPANOSOMAL AGENT;

ANIMAL CELL; ANTILEISHMANIAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG TARGETING; ERYTHROCYTE; HEMOLYSIS; INFRARED SPECTROSCOPY; LEISHMANIA CHAGASI; MOUSE; NANOENGINEERING; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PROCESS OPTIMIZATION; PRODUCT DEVELOPMENT; SCANNING TRANSMISSION ELECTRON MICROSCOPY; STATIC ELECTRICITY; ZETA POTENTIAL; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG EFFECTS; FEMALE; HUMAN; LEISHMANIA INFANTUM; LEISHMANIA MEXICANA; LEISHMANIASIS; MACROPHAGE; MEDICINAL CHEMISTRY; NANOMEDICINE; PARASITOLOGY; ULTRASTRUCTURE;

AMPHOTERICIN B; ANIMALS; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; CHONDROITIN SULFATES; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LEISHMANIA INFANTUM; LEISHMANIA MEXICANA; LEISHMANIASIS; MACROPHAGES; MICE; MICE, INBRED BALB C; NANOMEDICINE; NANOPARTICLES; TRYPANOCIDAL AGENTS;

EID: 84896823295     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S55678     Document Type: Article

References (61)

1. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis. 2004;27(5):305-318.
2. World Health Organization (WHO). Control of the Leishmaniases: Report of a Meeting of the 399 WHO Expert Committee on the Control of Leishmaniases, Geneva, 22-26 March 2010. WHO 400 Technical Report Series 949. Geneva: WHO; 2010. Available from: whqlibdoc.who.int/trs/WHO_TRS_949_eng.pdf. Accessed December 18, 2013.
3. Alvar J, Vélez ID, Bern C, et al; WHO Leishmaniasis Control Team. Leishmaniasis worldwide and global estimates of its incidence. PloS One. 2012;7(5):e35671.
4. Croft SL, Coombs GH. Leishmaniasis current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. 2003;19(11): 502-508.
5. Grevelink SA, Lerner EA. Leishmaniasis. J Am Acad Dermatol. 1996; 34(2):257-272.
6. Annaloro C, Olivares C, Usardi P, et al. Retrospective evaluation of amphotericin B deoxycholate toxicity in a single centre series of haematopoietic stem cell transplantation recipients. J Antimicrob Chemother. 2009;63(3):625-626.
7. Denning DW. Therapeutic outcome of invasive aspergillosis. Clin Infect Dis. 1996;23(3):608-615.
8. Bern C, Adler-Moore J, Berenguer J, et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis. 2006;43(7):917-924.
9. Egger SS, Meier S, Leu C, et al. Drug interactions and adverse events associated with antimycotic drugs used for invasive aspergillosis in hematopoietic SCT. Bone Marrow Transplant. 2009;45(7): 1197-1203.
10. Italia JL, Sharp A, Carter KC, Warn P, Kumar MN. Peroral amphotericin B polymer nanoparticles lead to comparable or superior in vivo antifungal activity to that of intravenous Ambisome® or Fungizone™. PLoS One. 2011;6(10):e25744.
11. Quintanar-Guerrero D, Allémann E, Fessi H, Doelker E. Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers. Drug Dev Ind Pharm. 1998;24(12):1113-1128.
12. de Carvalho RF, Ribeiro IF, Miranda-Vilela AL, et al. Leishmanicidal activity of amphotericin B encapsulated in PLGA-DMSA nanoparticles to treat cutaneous leishmaniasis in C57BL/6 mice. Exp Parasitol. 2013;135(2):217-222.
13. Asthana S, Jaiswal AK, Gupta PK, Pawar VK, Dube A, Chourasia MK. Immunoadjuvant chemotherapy of visceral leishmaniasis in hamsters using amphotericin B-encapsulated nanoemulsion template-based chitosan nanocapsules. Antimicrob Agents Chemother. 2013;57(4): 1714-1722.
14. Shao K, Huang R, Li J, et al. Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain. J Control Release. 2010;147(1):118-126.
15. Yang ZL, Li XR, Yang KW, Liu Y. Amphotericin B-loaded poly(ethylene glycol)-poly(lactide) micelles: preparation, freeze-drying, and in vitro release. J Biomed Mater Res A. 2008;85(2):539-546.
16. Kreuter J. Nanoparticles. In: Swarbrick J, Boylan JC, editors. Encyclopedia of Pharmaceutical Technology. New York, NY: Marcel Dekker; 1988:165-190.
17. Janes KA, Fresneau MP, Marazuela A, Fabra A, Alonso MJ. Chitosan nanoparticles as delivery systems for doxorubicin. J Control Release. 2001;73(2-3):255-267.
18. St John AL, Chan CY, Staats HF, Leong KW, Abraham SN. Synthetic mast-cell granules as adjuvants to promote and polarize immunity in lymph nodes. Nat Mater. 2012;11(3):250-257.
19. Huang L, Sui W, Wang Y, Jiao Q. Preparation of chitosan/chondroitin sulfate complex microcapsules and application in controlled release of 5-fluorouracil. Carbohydr Polym. 2010;80(1):168-173.
20. Ganza-González A, Anguiano-Igea S, Otero-Espinar FJ, Blanco Méndez J. Chitosan and chondroitin microspheres for oral-administration controlled release of metoclopramide. Eur J Pharm Biopharm. 1999;48(2):149-155.
21. Sui W, Huang L, Wang J, Bo Q. Preparation and properties of chitosan chondroitin sulfate complex microcapsules. Colloids Surf B Biointerfaces. 2008;65(1):69-73.
22. Yeh MK, Cheng KM, Hu CS, Huang YC, Young JJ. Novel protein-loaded chondroitin sulfate-chitosan nanoparticles: preparation and characterization. Acta Biomater. 2011;7(10):3804-3812.
23. Hu CS, Chiang CH, Hong PD, Yeh MK. Influence of charge on FITC BSA-loaded chondroitin sulfate-chitosan nanoparticles upon cell uptake in human Caco-2 cell monolayers. Int J Nanomedicine. 2012;7: 4861-4872.
24. Tsai HY, Chiu CC, Lin PC, Chen SH, Huang SJ, Wang LF. Antitumor efficacy of doxorubicin released from crosslinked nanoparticulate chondroitin sulfate/chitosan polyelectrolyte complexes. Macromol Biosci. 2011;11(5):680-688.
25. Bhattarai N, Gunn J, Zhang M. Chitosan-based hydrogels for controlled, localized drug delivery. Adv Drug Deliv Rev. 2010;62(1):83-99.
26. Thongngam M, McClements DJ. Influence of pH, ionic strength, and temperature on self-association and interactions of sodium dodecyl-sulfate in the absence and presence of chitosan. Langmuir. 2005;21(1):79-86.
27. Iovu M, Dumais G, du Souich P. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage. 2008;16 Suppl 3:S14-S18.
28. Ronca F, Palmieri L, Panicucci P, Ronca G. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage. 1998;6 Suppl A:14-21.
29. Ronca F, Palmieri L, Panicucci P, Ronca G. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartigale. 1998;6(A):14-21.
30. Kirker KR, Luo Y, Morris SE, Shelby J, Prestwich GD. Glycosaminoglycan hydrogels as supplemental wound dressings for donor sites. J Burn Care Rehab. 2004;25(3):276-286.
31. Kirker KR, Luo Y, Nielson JH, Shelby J, Prestwich GD. Glycosaminoglycan hydrogel films as bio-interactive dressings for wound healing. Biomaterials. 2002;23(17):3661-3671.
32. Wang LF, Wang JM, Chiang YL. Insolubilization of sodium chondroitin sulfate by forming a semi-interpenetrating polymer network with acrylic acid: a potential carrier for colon-specific drug delivery. J Appl Polym Sci. 2002;85(1):114-122.
33. Sintov A, Di-Capua N, Rubinstein A. Cross-linked chondroitin sulphate: characterization for drug delivery purposes. Biomaterials. 1995;16(6):473-478.
34. Costa DF, Franca JR, Ribeiro TG, Kaplan MA, Faraco AA, Castilho RO. Development and characterization of polymeric nanoparticles as Barbatimão (Stryphnodendron obovatum) standardized fraction carrier. Adv Biosci Biotechnol. 2012;4(1):89-92.
35. Calvo P, Remuñán-López C, Vila-Jato JL, Alonso MJ. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J Appl Polym Sci. 1997;63(1):125-132.
36. Grenha A, Gomes ME, Rodrigues M, et al. Development of new chitosan/carrageenan nanoparticles for drug delivery applications. J Biomed Mater Res A. 2010;92(4):1265-1272.
37. Müller RH, Schmidt S, Buttle I, Akkar A, Schmitt J, Brömer S. SolEmuls-novel technology for the formulation of iv emulsions with poorly soluble drugs. Int J Pharm. 2004;269(2):293-302.
38. Moreno MA, Frutos P, Ballesteros MP. Lyophilized lecithin based oil-water microemulsions as a new and low toxic delivery system for amphotericin B. Pharm Res. 2001;18(3):344-351.
39. Santos CM, Oliveira RB, Arantes VT, et al. Amphotericin B-loaded nanocarriers for topical treatment of cutaneous leishmaniasis: development, characterization, and in vitro skin permeation studies. J Biomed Nanotechnol. 2012;8(2):322-329.
40. Nahar M, Jain NK. Preparation, characterization and evaluation of targeting potential of amphotericin B-loaded engineered PLGA nanoparticles. Pharm Res. 2009;26(12):2588-2598.
41. Coelho EA, Tavares CA, Carvalho FA, et al. Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection. Infect Immun. 2003;71(7):3988-3994.
42. Valadares DG, Duarte MC, Oliveira JS, et al. Leishmanicidal activity of the Agaricus blazei Murill in different Leishmania species. Parasitol Int. 2011;60(4):357-363.
43. Fumarola L, Spinelli R, Brandonisio O. In vitro assays for evaluation of drug activity against Leishmania spp. Res Microbiol. 2004;155(4): 224-230.
44. Löfgren SE, Miletti LC, Steindel M, Bachère E, Barracco MA. T{stroke}rypanocidal and leishmanicidal activities of different antimicrobial peptides (AMPs) isolated from aquatic animals. Exp Parasitol. 2008;118(2):197-202.
45. Jung SH, Lim DH, Jung SH, et al. Amphotericin B-entrapping lipid nanoparticles and their in vitro and in vivo characteristics. Eur J Pharm Sci. 2009;37(3-4):313-320.
46. Onishi H, Machida Y. Biodegradation and distribution of water-soluble chitosan in mice. Biomaterials. 1999;20(2):175-182.
47. Huang M, Ma Z, Khor E, Lim LY. Uptake of FITC-chitosan nanoparticles by A549 cells. Pharm Res. 2002;19(10):1488-1494.
48. Adams ML, Kwon GS. Relative aggregation state and hemolytic activity of amphotericin B encapsulated by poly(ethylene oxide)-block-poly(Nhexyl-L-aspartamide)-acyl conjugate micelles: effects of acyl chain length. J Control Release. 2003;87(1-3):23-32.
49. Tasdemir D, Kaiser M, Brun R, et al. Antitrypanosomal and antileishmanial activities of flavonoids and their analogues: in vitro, in vivo, structure-activity relationship, and quantitative structureactivity relationship studies. Antimicrob Agents Chemother. 2006;50(4): 1352-1364.
50. Pujals G, Suñé-Negre JM, Pérez P, et al. In vitro evaluation of the effectiveness and cytotoxicity of meglumine antimoniate microspheres produced by spray drying against Leishmania infantum. Parasitol Res. 2008;102(6):1243-1247.
51. Nakajima A, Shinoda K. Complex formation between oppositely charged polysaccharides. J Colloid Interface Sci. 1976;55(1):126-132.
52. Chen WB, Wang LF, Chen JS, Fan SY. Characterization of polyelectrolyte complexes between chondroitin sulfate and chitosan in the solid state. J Biomed Mater Res A. 2005;75(1):128-137.
53. Mazerski J, Grzybowska J, Borowski E. Influence of net charge on the aggregation and solubility behaviour of amphotericin B and its derivatives in aqueous media. Eur Biophys J. 1990;18(3):159-164.
54. Batrakova EV, Gendelman HE, Kabanov AV. Cell-mediated drug delivery. Expert Opin Drug Deliv. 2011;8(4):415-433.
55. Danesh-Bahreini MA, Shokri J, Samiei A, Kamali-Sarvestani E, Barzegar-Jalali M, Mohammadi-Samani S. Nanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/c mice. Int J Nanomedicine. 2011;6:835-842.
56. Wise DL, editor. Handbook of Pharmaceutical Controlled Release Technology. New York, NY: Marcel Dekker, 2000; Chap 9: pp 183-210.
57. Jogani V, Jinturkar K, Vyas T, Misra A. Recent patents review on intranasal administration for CNS drug delivery. Recent Pat Drug Deliv Formul. 2008;2(1):25-40.
58. Legrand P, Romero EA, Cohen BE, Bolard J. Effects of aggregation and solvent on the toxicity of amphotericin B to human erythrocytes. Antimicrob Agents Chemother. 1992;36(11):2518-2522.
59. Darole PS, Hegde DD, Nair HA. Formulation and evaluation of microemulsion based delivery system for amphotericin B. AAPS Pharm Sci Tech. 2008;9(1):122-128.
60. Van de Ven H, Paulussen C, Feijens PB, et al. PLGA nanoparticles and nanosuspensions with amphotericin B: Potent in vitro and in vivo alternatives to Fungizone and AmBisome. J Control Release. 2012;161(3): 795-803.
61. Corware K, Harris D, Teo I, et al. Accelerated healing of cutaneous leishmaniasis in non-healing BALB/c mice using water soluble amphotericin B-polymethacrylic acid. Biomaterials. 2011;2(31): 8029-8039.